Adial Pharmaceuticals

Charlottesville, United States Founded: 2010 • Age: 16 yrs Listed
Therapeutics for addiction treatment are developed by Adial Pharmaceuticals.

About Adial Pharmaceuticals

Adial Pharmaceuticals is a publicly listed company based in Charlottesville (United States) founded in 2010 by Bankole Johnson. Therapeutics for addiction treatment are developed by Adial Pharmaceuticals. Adial Pharmaceuticals has raised $7.7 million across 15 funding rounds from investors including Keystone Capital Partners, Coastlands Capital and Boxer Capital. The company has 7 employees. Adial Pharmaceuticals has completed 1 acquisition, including Azora Therapeutics. Adial Pharmaceuticals offers products and services including AD04. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its legal entity is Adial Pharmaceuticals, Inc. Its competitors include Indivior, Braeburn and Amygdala Neurosciences; 2 of its 3 listed competitors have raised funding.

Company details

Adial Pharmaceuticals was founded in 2010 and is headquartered in Charlottesville, United States. Therapeutics for addiction disorders are developed, with a focus on genetically targeted drugs such as AD04 for alcohol use disorder. Adenosine analogues under the Purnovate platform are also pursued for inflammatory and neurotransmission-related conditions. Operations center on pharmaceutical research and development in the biotech sector.

  • Headquarters Charlottesville, United States
  • Employees 7
  • Founders Bankole Johnson
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website adial.com
  • Social LinkedIn X YouTube
  • Legal Name Adial Pharmaceuticals, Inc.
Operational Areas
Key Metrics
  • Net Profit
    -$7.98 M (USD)
    39.56
    as on Dec 31, 2025
  • EBITDA
    -$7.8 M (USD)
    5.85
    as on Dec 31, 2025
  • Total Equity Funding
    $7.7M (USD)

    in 15 rounds

  • Latest Funding Round
    $64M (USD), Post-IPO

    Jun 2026

  • Investors
  • Employee Count
    7
  • Investments & Acquisitions

Products & Services of Adial Pharmaceuticals

Adial Pharmaceuticals offers a comprehensive portfolio of products and services, including AD04.

AD04
Therapeutic Agent

Genetically targeted treatment for alcohol use disorder via serotonin receptor antagonism

Apps and channels of Adial Pharmaceuticals

its YouTube channel Adial Pharmaceuticals has 163 subscribers and 26 videos.

Adial Pharmaceuticals
YouTube 163 subscribers 26 videos Science & Technology
Open channel

Videos from Adial Pharmaceuticals

The most watched videos on Adial Pharmaceuticals's YouTube channel, Adial Pharmaceuticals (163 subscribers). Click a video to play it here.

Aligning Visions: How Adial Approaches Industry Collaboration
8.5K views
Advancing Precision Medicine for Alcohol Use Disorder with AD04
6.3K views
Adial’s Next Chapter: U.S. Manufacturing and Long-Term IP Protection
5.4K views
Empowering Patients: How Community Engagement Reduces Stigma
4.7K views

More on Adial Pharmaceuticals.

Funding Insights of Adial Pharmaceuticals

Adial Pharmaceuticals has successfully raised a total of $7.7M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $64 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $7.7M
  • Total Rounds 15
  • Last Round Post-IPO — $64M
  • First Round $4.1M

    (Mar 2011)

  • Investors Count 4

Latest 10 of 15 funding rounds of Adial Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2026$64MPost-IPO–Coastlands Capital
Mar 2024$287,500Post-IPO––
–
Jun 2023$52,500Post-IPO––
–
Nov 2021$800,000Post-IPO––
–
Jul 2021$5MPost-IPO––
–
Mar 2021$2.1MPost-IPO––
Nov 2020$295,750Post-IPO––
–
Sep 2020$500,000Post-IPO––
–
Jun 2018$325,000Series A––
–
Feb 2018$500,000Series A––
–
Valuation history

4 investors in total: 4 institutional.

Investors in Adial Pharmaceuticals

Adial Pharmaceuticals has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Keystone Capital Partners, Coastlands Capital and Boxer Capital.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
An investment firm based in New York is operated.
keystone-cp.comNew York, United States
coastlandscapital.com
boxercap.com
stonepinecap.com
Premium access

Investor details for Adial Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Adial Pharmaceuticals

1 people are tracked at Adial Pharmaceuticals (1 in leadership); the tracked headcount is 7.

NameRoleGroup
Bankole Johnson
FounderLeadership
Premium access

Complete people profiles for Adial Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Adial Pharmaceuticals

Adial Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ADIL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date27 Jul 2018
  • Listed onNASDAQ: ADIL
  • Listed entityAdial Pharmaceuticals, Inc
  • Exchange sectorHealth technology

Investments & Acquisitions by Adial Pharmaceuticals

Adial Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Azora Therapeutics.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Small molecule therapies for autoinflammatory diseases are developed.
azoratherapeutics.comLos Angeles, United States2019Jun 2026••••
Premium access

Complete acquisition details for Adial Pharmaceuticals

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Adial Pharmaceuticals

5 dated milestones of Adial Pharmaceuticals across 16 years, from founding to its latest funding, stage changes and deals.

  1. Founded Adial Pharmaceuticals is founded.
  2. Funding First funding round of $4.1M.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $64.0M.
  5. Acquisition Acquires Azora Therapeutics.

Competitors of Adial Pharmaceuticals

Adial Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Indivior, Braeburn and Amygdala Neurosciences.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
indivior.com2014Richmond Hill, United States1,051
Therapeutics for opioid addiction treatment are developed and commercialized.
braeburnrx.com2012Philadelphia, United States$110M
Long-acting therapies for opioid addiction and chronic pain are developed.
amygns.com2015San Francisco, United States$7.05M
Therapies for substance use disorders are developed by Amygdala Neurosciences.
Premium access

Detailed competitors of Adial Pharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Adial Pharmaceuticals

The website of Adial Pharmaceuticals (adial.com) receives about 2.6K visits a month.

  • Monthly visits
    2.6K

    ▼ 26.1% vs previous month

Top companies in Neurology

3 companies that operate in the same segment as Adial Pharmaceuticals (Neurology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Developer of therapeutics for psychiatric and neurologic diseases
2002New York, New York, United StatesUSD 80.87 MUSD 250.31 M600
Biologics platform developed for intracellular delivery in rare diseases.
2016Boston, Massachusetts, United StatesUSD 175.25 MUSD 25.42 M183
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Adial Pharmaceuticals

Premium access

Complete news archive for Adial Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Adial Pharmaceuticals

Adial Pharmaceuticals was founded in 2010 and raised its 1st funding round 1 year after it was founded.

Adial Pharmaceuticals is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.

Adial Pharmaceuticals is a funded company, having raised a total of $7.7M across 15 funding rounds to date. The company's 1st funding round was a Series A of $500K, raised on Mar 2011.

Adial Pharmaceuticals has 7 employees.

Adial Pharmaceuticals was founded in 2010 and is headquartered in Charlottesville, United States. Therapeutics for addiction disorders are developed, with a focus on genetically targeted drugs such as AD04 for alcohol use disorder. Adenosine analogues under the Purnovate platform are also pursued for inflammatory and neurotransmission-related conditions. Operations center on pharmaceutical research and development in the biotech sector.

Adial Pharmaceuticals's top competitors include Indivior, Amygdala Neurosciences and Braeburn.

Adial Pharmaceuticals offers AD04.

Yes, Adial Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ADIL.

Adial Pharmaceuticals has made 1 acquisition, including Azora Therapeutics.

Adial Pharmaceuticals has 4 investors. Key investors include Keystone Capital Partners, Coastlands Capital, Boxer Capital, and Stonepine.

Adial Pharmaceuticals operates through Adial Pharmaceuticals, Inc..

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available